Fig. 8
From: Raptor mediates the selective inhibitory effect of cardamonin on RRAGC-mutant B cell lymphoma
Inhibition mechanism of cardamonin on the RagCT90N-mutant cell. (Left) In normal cells, the “active” RagA·GTP-RagC·GDP heterodimer binds with Raptor, following the activation of mTOR in the presence of amino acids. (Right) RagC mutation increases its binding capacity with Raptor, which ultimately elicits hyperactivated mTORC1 signalling and enhancing the cell proliferation of lymphoma cells. Cardamonin decreases the protein level of Raptor and further disrupts the formation of mTOR activating complex. Pharmacological inhibition of mTORC1 by cardamonin exerts selective therapeutic effects on the RagCT90N-mutant lymphoma cells